Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest Benzamides Stories

2013-10-28 08:28:06

CALGARY, Oct. 28, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced a poster presentation containing updated efficacy data from a Phase 2 study examining the use of REOLYSIN(®) in combination with carboplatin and paclitaxel in patients with stage IV non-small cell lung cancer (NSCLC) with Kras or EGFR-activated tumors (REO 016) was made at International Association for the Study of Lung Cancer (IASLC). The conference is being held...

2013-10-21 12:27:25

Presentations to Highlight Data from Two Recently Completed Clinical Trials for Company's Lead Rheumatoid Arthritis Products CHICAGO, Oct. 21, 2013 /PRNewswire/ -- Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced today that data from two recently completed clinical trials for its lead product will be presented during the 2013 American College of Rheumatology...

2013-10-17 16:30:52

NEJM today publishes findings of international trial resulting in recent FDA approval of Abraxane (nab-paclitaxel) for patients with advanced pancreatic cancer By all measures, the addition of nab-paclitaxel for the treatment of patients with advanced pancreatic cancer was superior to the survival for patients who received only gemcitabine, according to the results of a study led by the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare, published today by The New...

DEET Alternatives Of The Future
2013-10-03 04:27:36

[ Watch the Video: UC Riverside Research Team Identifies DEET Receptors ] redOrbit Staff & Wire Reports - Your Universe Online In research that could lead to the development of a safer alternative to the DEET, scientists from the University of California, Riverside have discovered the olfactory receptors used by insects to sense the repellant. While experts have long known that bugs are repelled by DEET (also known as N,N-diethyl-m-toluamide), UC-Riverside associate professor of...

2013-09-16 08:28:33

SAN DIEGO, Sept. 16, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC QB: SRNE; Sorrento) announced today it will present the clinical data for Cynviloq(TM) (IG-001), which resulted in its approval as 1(st) line treatment of ovarian cancer by Korean FDA in March of 2013. Highlights of the findings include proof of non-inferiority of Cynviloq vs. Taxol in combination therapy with Carboplatin in patients with advanced epithelial ovarian cancer. These data will be presented at the...

2013-09-12 08:32:21

SAN DIEGO, Sept. 12, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that clinical data from a Phase 1b trial of PEGPH20 (PEGylated recombinant human hyaluronidase) in combination with gemcitabine for the treatment of patients with stage IV metastatic pancreatic cancer will be presented at the European Cancer Congress 2013 (ECCO-ESMO-ESTRO) in Amsterdam. Additional data, including progression free and overall survival by hyaluronan (HA) status, will be...

Control Annoying Pests With A Scoop Of Grapefruit
2013-09-11 15:10:26

Lee Rannals for redOrbit.com - Your Universe Online Grapefruit may be the key in a new battle against mosquitoes, ticks, head lice and bedbugs, according to research presented at the 246th National Meeting & Exposition of the American Chemical Society. Scientists say the citrus flavor and aroma of grapefruit may find a new use in battling the pests due to less expensive ways of making the ingredient, nootkatone. This ingredient previously had to be harvested from tons of grapefruit,...

2013-09-10 08:30:25

SAN DIEGO, Sept. 10, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC QB: SRNE; Sorrento) announced today that it has secured an option to an exclusive license for the worldwide rights to Biomiga Diagnostics' (Biomiga) proprietary therapeutic drug monitoring (TDM) device for paclitaxel products. The license and option agreement allows Sorrento to utilize the TDM device for the clinical development of individualized dosing regimens of Sorrento's late-stage compound, Cynviloq(TM)...

2013-09-10 08:29:38

SAN DIEGO, Sept. 10, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC QB: SRNE; Sorrento) announced today that it has completed the merger with IgDraSol, Inc., a privately-held company focused on the development of cancer therapeutics. Upon the closing of the merger, IgDraSol shareholders will receive the equivalent of 3,047,968 million shares of Sorrento's common stock. Such issuance reflects Sorrento's recent reverse stock split, and based on the closing share price on...

2013-09-06 20:20:58

Abraxane now part of standard-of-care for patients with advanced pancreatic cancer, following studies at the Virginia G. Piper Cancer Center at Scottsdale Healthcare SCOTTSDALE, Ariz., Sept. 6, 2013 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Abraxane for patients with advanced pancreatic cancer, following 7 years of rigorous clinical trials overseen by Scottsdale Healthcare and the Translational Genomics Research Institute (TGen). (Logo:...